COLL

AI Memo

Collegium Pharmaceutical

As of 2026-09-16/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Accelerated share-repurchase settlement • 2026-12-31

Base target: $23 / p=50% prob

Biggest risk

The secondary earnings context reported a revenue miss, substantial post-print share-price weakness and pressure on NUCYNTA economics. Failure to convert back-to-school promotion into durable AZSTARYS and JORNAY PM growth would leave the company exposed to pain-franchise erosion and integration risk.

Invalidation

Break below $17 or thesis failure.

What would change my mind?

ADHD diversification is gaining traction: Q2 JORNAY PM revenue rose 41%, prescriber reach expanded, and AZSTARYS added a complementary product to the commercial platform. Sustained prescription growth could support a rerating from the depressed post-earnings level. [#SEC-8K-2026-08-06]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-16

Base target

$23

p=50%

Bull target

$30

p=25%

Bear target

$17

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 ADHD portfolio execution
ADHD-led portfolio diversification
ADHD diversification is gaining traction: Q2 JORNAY PM revenue rose 41%, prescriber reach expanded, and AZSTARYS added a complementary product to the commercial platform.

BearKey bullets

AZSTARYS integration and commercial execution may not produce the expected prescription acceleration.
Further acquisitions or business-development spending could introduce leverage, integration or capital-allocation risk.
NUCYNTA revenue pressure from authorized-generic pricing could outweigh ADHD growth.

WatchKey bullets

Accelerated share-repurchase settlement

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $23 (p=50%)

Target spread vs base: +29% / -29%

Scenario probabilities

Bull Target: $30 (p=25%)Base Target: $23 (p=50%)Bear Target: $17 (p=25%)

Commentary

Recent coverage remains concentrated on Q2 results. Stored secondary context described a negative market reaction despite an adjusted-EPS beat and increased revenue guidance, while the September 15 anchor of $21.84 is below the cited post-earnings level. No sufficient social coverage, options skew, short-interest data, employee score or verified post-print analyst revisions were supplied; unavailable sentiment fields are represented as neutral placeholders and should not be interpreted as measured observations. The evidence supports cautious positive monitoring rather than a high-conviction rerating thesis.

As of 2026-09-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 ADHD portfolio execution
ADHD-led portfolio diversification

Scenarios

Bull Target (Scenario probability)

$30 / p=25% prob

Base Target (Scenario probability)

$23 / p=50% prob

Bear Target (Scenario probability)

$17 / p=25% prob

Analysis 2026-09-16 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Accelerated share-repurchase settlement
Final settlement of the accelerated share-repurchase agreement is expected no later than the fourth quarter of 2026, creating a defined capital-allocation checkpoint but not an operating catalyst. [#8-K-2026-08-13]
Prob 85.00% • Move 3.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Q3 ADHD portfolio execution
2026-11-15
The next operating test is whether back-to-school demand sustains JORNAY PM growth and accelerates AZSTARYS after salesforce integration. Q2 JORNAY PM revenue increased 41% year over year, prescribers increased 17.6%, and AZSTARYS contributed $12.9 million for a partial quarter. [#SEC-8K-2026-08-06]
Prob 65% • Move 10% • Priced-in 45%

Long-term Catalysts

Months to a year

ADHD-led portfolio diversification
2027-08-31
Sustained JORNAY PM growth and successful AZSTARYS commercialization could reduce reliance on the pain portfolio. The Q2 release reported record JORNAY PM adoption, completed AZSTARYS integration and an expanded commercial platform, while also acknowledging increased NUCYNTA pressure. [#SEC-8K-2026-08-06]
Prob 55% • Move 25% • Priced-in 35%

Risks

AZSTARYS integration and commercial execution may not produce the expected prescription acceleration.
Further acquisitions or business-development spending could introduce leverage, integration or capital-allocation risk.
NUCYNTA revenue pressure from authorized-generic pricing could outweigh ADHD growth.
Pain-portfolio intellectual-property exposure, including secondary discussion of potential Belbuca generic entry in 2027, may compress the durability of cash flows.
The packet lacks verified post-earnings analyst revisions, detailed forward estimates and close operating peers.

Peers

Symbol	Summary
ABUS	Similar market capitalization and sector classification, but its biotechnology profile is not a close operating comparison for Collegium's commercial portfolio.
AMPH	Similar-sized commercial pharmaceutical company, but the packet does not establish direct ADHD or pain-product overlap; valuation comparisons should therefore receive limited weight.
CADL	Similar market capitalization but lacks demonstrated therapeutic or commercial comparability, making it only broad small-cap biopharma context.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-16

Loading AI feed…

Symbol

Summary

ABUS

Similar market capitalization and sector classification, but its biotechnology profile is not a close operating comparison for Collegium's commercial portfolio.

AMPH

Similar-sized commercial pharmaceutical company, but the packet does not establish direct ADHD or pain-product overlap; valuation comparisons should therefore receive limited weight.

CADL

Similar market capitalization but lacks demonstrated therapeutic or commercial comparability, making it only broad small-cap biopharma context.